DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Acipimox
Acipimox
Full Text
No Name of Drug Branded/Generic Drug Class 1 Acipimox Capsule 250Mg Olbetam Nicotinic Acid 1.50 2.14 2 Atorvastatin Calcium 10Mg
Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes?
PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
PRAC Recommends Using Acipimox Only As Additional Or Alternative Treatment to Lower High Triglyceride Levels Licensed Uses Should Be Refined to Optimise Benefit-Risk
Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research
Reassessment of Reimbursement Status for Lipid-Lowering Medicines, ATC Group C10 Introduction by the End of 20041, the Danish Pa
Effect of Acipimox on Plasma Lipids and Glucose/Insulin in Pregnant Rats
Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
Rosuvastatin Zinc Salt Rosuvastatin-Zinksalz Sel De Zinc De Rosuvastatine
Acipimox (Olbetam®)
ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
Risk of Cataract in Patients Treated with Statins
Cholesterol-Lowering Drugs and Prostate Cancer Risk: a Population-Based Case-Control Study
Recommendation from the New Drugs Committee
No Name of Drug Branded/Generic Drug Class 1 Acipimox Capsule 250Mg Olbetam Nicotinic Acid 1.50 2.14 2 Atorvastatin Calcium 10Mg
Anatomical Classification Guidelines V2016
Top View
Pathophysiology and Treatment of Atherosclerosis Current View and Future Perspective on Lipoprotein Modification Treatment
Accessibility Improving Information Using Online Patient Drug Reviews
Combinations of Ileal Bile Acid Transport Inhibitors and Bile Acid Sequestering Agents for Cardiovascular Indications
Changes Highlighted Final Version Date of Issue
Ep 1 599 469 B1
Cholecystectomy Statin Use and Risk of Gallstone Disease Followed By
V007 1. NAME of the MEDICINAL PRODUCT Ezetimibe/ Simvastatin 10 Mg/10 Mg Tablets Ezetimibe/Simvastatin 10 Mg/20 Mg Tablets Ezeti
Guidelines for the Management of Lipid Disorders (Dyslipidaemia) for General Practitioners
Improving Information Accessibility Using Online Patient Drug Reviews
Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark∗
No Name of Drug Branded/Generic Drug Class 1 Acipimox Capsule 250Mg Olbetam Nicotinic Acid 1.53 1.60 2 Atorvastatin Calcium 10Mg
(2020) [1] Kim CH, Kang SI, Shin D. Pharmacokinetic Interaction Between Telmisartan and Rosuvastatin/E
New Zealand Data Sheet
Evidence for a Direct Effect of the NAD+ Precursor Acipimox on Muscle Mitochondrial Function in Humans
Re-Submission Nicotinic Acid Modified Release Tablets (Niaspanò) No
Trends in Lipid-Modifying Agent Use in 83 Countries
Treatment Guidelines for Dyslipidemia: Summary of the Expanded Second Version
Information for the User OLBETAM® 250 Mg Capsules Acipimox Read
Clinical Pharmacologyand Therapeutics
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Download Report Appendixes [PDF · 3.8
WO 2008/030382 Al
ICD-10-CM Table of Drugs 2019
Ivermectin Interest Group Submission
Literature Update Week 13 (2019)
Nicotinic Acid and Related Substances Art 31
Consultation on the Reimbursement Committee's Recommendations
Familial Hypercholesterolaemia a RESEARCH REVIEW™ EDUCATIONAL SERIES
Ezetimibe for the Treatment of Hypercholesterolaemia Vol
Hypercholesterolemia.Af
The Impact Ofa Short Course of Three Lipid Lowering Drugs
Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
Pathophysiology and Treatment of Atherosclerosis Current View and Future Perspective on Lipoprotein Modification Treatment
Desk Based Review of Current Knowledge on Pharmaceuticals in Drinking Water and Estimation of Potential Levels
Acipimox Only to Be Used As Additional Or Alternative Treatment to Reduce High Triglyceride Levels Cmdh Endorses PRAC Recommendation